Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12894510 | 0.74 | ALDH1A1 (0.45) | ALDH1A1NPSR1HSD17B10MAPTKDM4E | |
| SCHEMBL26619213 | 0.70 | ALDH1A1 (0.41) | ALDH1A1CES1NPSR1HSD17B10MAPT | |
| SCHEMBL3100377 | 0.69 | ALDH1A1 (0.47) | ALDH1A1HSD17B10HSP90AA1MAPTKDM4E | |
| SCHEMBL3071590 | 0.67 | MAPT (0.41) | HSP90AA1MAPTRECQL | |
| SCHEMBL19370404 | 0.66 | ALDH1A1 (0.44) | ALDH1A1CES1NPSR1HSD17B10MAPT | |
| SCHEMBL4164158 | 0.66 | HSP90AA1 (0.45) | ALDH1A1NPSR1HSD17B10HSP90AA1MAPT | |
| SCHEMBL2218602 | 0.66 | KMT2A (0.38) | ALDH1A1NPSR1MAPTKDM4ERXFP1 | |
| SCHEMBL18352875 | 0.65 | CES1 (0.42) | ALDH1A1CES1NPSR1HSD17B10MAPT | |
| SCHEMBL24370289 | 0.65 | MAPT (0.39) | ALDH1A1NPSR1MAPTKDM4ETSHR | |
| SCHEMBL2692004 | 0.65 | ALDH1A1 (0.50) | ALDH1A1NPSR1HSD17B10HSP90AA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216970-B2 | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216970-B2 | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150105392-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105392-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-04-16 | — | — | US | disclosed |
| US-8946233-B2 | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946233-B2 | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140135333-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135333-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8664227-B2 | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents | THERAVANCE, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664227-B2 | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents | THERAVANCE, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130267539-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267539-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-8481549-B2 | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents | THERAVANCE, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481549-B2 | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents | THERAVANCE, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| WO-2011090929-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20110178101-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-07-21 | — | — | US | disclosed |
| US-20110178101-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178101-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | REN, AGTR1, AGTR2 | ALDH1A1 2122/4885CES1 1943/4885NPSR1 36/4885 |
| US-20140135333-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | REN, AGTR1, AGTR2 | ALDH1A1 2122/4885CES1 1943/4885NPSR1 36/4885 |
| US-20130267539-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | REN, AGTR1, AGTR2 | ALDH1A1 2122/4885CES1 1943/4885NPSR1 36/4885 |
| US-20150105392-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | REN, AGTR1, AGTR2 | ALDH1A1 2122/4885CES1 1943/4885NPSR1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.